Dr. Reddy’s to Apply Aegis’ Intravail Delivery Technology to Marketed Therapeutics
Company is targeting medications that together made over $1 billion in sales annually.!--h2>
Dr. Reddy’s Laboratories negotiated access to Aegis Therapeutics’ Intravail® drug-delivery technology for use with specific marketed therapeutics that currently represent annual worldwide sales of over $1 billion.
Intravail comprises a broad class of chemically synthesized transmucosal absorption enhancement agents. Aegis claims the technology enables the noninvasive systemic delivery of peptide, protein, nucleotide, or other small/large molecule drugs that have been deliverable by injection only until now.
The company also states it has proven the feasibility of using Intravail to deliver a broad range of therapeutics of up to 30,000 Daltons molecular weight. These include calcitonin, growth hormone, leptin, PTH, insulin, erythropoietin, PYY-3-36, GLP-1 related peptides, glucagon, antisense drugs, and low molecular weight heparins.
Aegis’ drug-delivery technologies also include its ProTek® protein- and peptide-stabilization excipients and Aegis Hydrogels™, which have been developed as absorption-enhancing, self-assembling nonpolymeric hydrogels.
In December 2009, the company signed a licensing agreement with Roche, giving the latter access to its ProTek technology. The deal covers the use of specific excipients as stabilizers in certain manufacturing processes and formulations of protein-based therapeutics.